Adherence to the Standard Guidelines for Prescription of Antidiabetic Agents in Patients with Type 2 DM

Alhadidi, Qasim M.; Sahib, Ahmed S.; Jaffer, Ali M.; Ismael, Maha H.; Hassan, Ekhlas K.; Shareef, Saja M.; Shoesh, Asmaa M.; Dawood, Asia S.
July 2012
Journal of Applied Pharmaceutical Science;Jul2012, Vol. 2 Issue 7, p1
Academic Journal
Prescription of appropriate antihyperglycemic agent depending on the standard guidelines has an important role in controlling diabetes and improving patient health. The aim of the present prospective study is to follow-up the adherence of prescribers to the standard guidelines for the prescription of anti-diabetic drugs in patients with type 2 diabetes mellitus. A prospective clinical trial was carried out on 64 individuals (43 patients and 21 healthy volunteers) of both sexes with the age range from 40-70 years. Parameters followed-up were fasting blood glucose (FBG), lipid profile, liver and renal function tests. The values of these parameters (at admission and after 3 months of follow-up) were calculated and compared with that of the control group and with the recommended treatment goals stated by American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE/ ACE). Despite of continued treatment, no improvements were seen regarding followed-up parameters. It has been suggested that the adherence of prescribers to the standard guidelines for prescription of anti-diabetic agents is poor in our center, all patients evaluated have highly uncontrolled hyperglycemia where different anti-hyperglycemic drugs fail to attain glycemic control, and therapeutic strategy followed should be reconsidered.


Related Articles

  • Type 2 Diabetes: Updated Evidence Requires Updated Decision Making. SHAUGHNESSY, ALLEN F.; ERLICH, DEBORAH R.; SLAWSON, DAVID C. // American Family Physician;7/1/2015, Vol. 92 Issue 1, p22 

    The article comments on the paper "Management of blood glucose with noninsulin therapies in type 2 diabetes" by C. M. George and colleagues. Topics discussed include the small subset of patients who benefit from normalizing blood glucose levels, the tendency to over-treat hyperglycemia using...

  • UPDATE ON TREATMENT OF TYPE 2 DIABETES MELLITUS. RUNGBY, JORGEN // Problemy Endokrinologii;2017 Supplement, p6 

    Type 2 diabetes is a heterogeneous disease and therefore it may be complicated to treat hyperglycaemia. Treatment is ideally based on pathophysiological knowledge about the causes of hyperglycaemia in the individual patient: «The right pill in the right mouth». The lecture will focus on...

  • 11. The 2012 SEMDSA Treatment Algorithm for Type 2 Diabetes.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Jun2012, Vol. 17 Issue 2, pS36 

    The article discusses the development of the 2012 treatment algorithm for type 2 diabetes by the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA). It explores challenges faced by the committee in formulating the guideline for the pharmacological management of type 2...

  • No Need for the Needle (at First). Davidson, Mayer B. // Diabetes Care;Oct2008, Vol. 31 Issue 10, p2070 

    The author comments on a study by Chen et al. which describes an approach to the initial treatment of newly diagnosed type 2 diabetic patients with severe hyperglycemia entailing intensive insulin therapy during 10 to 14 days of hospitalization. According to the author, one should carefully...

  • Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review. Purnell, Tanjala S.; Joy, Susan; Little, Emily; Bridges, John F. P.; Maruthur, Nisa // Diabetes Care;Jul2014, Vol. 37 Issue 7, p2055 

    OBJECTIVE An evidence-based synthesis of patient preferences for management of hyperglycemia is needed. Our objective was to systematically review patient preferences for noninsulin diabetes medications in adults with type 2 diabetes. RESEARCH DESIGN AND METHODS We searched the PubMed, Embase,...

  • Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats. Mori, A.; Lee, P.; Yamashita, T.; Nishimaki, Y.; Oda, H.; Saeki, K.; Miki, Y.; Mizutani, H.; Ishioka, K.; Honjo, T.; Arai, T.; Sako, T. // Veterinary Research Communications;Dec2009, Vol. 33 Issue 8, p957 

    Glimepiride and nateglinide are two common oral hypoglycemic agents currently being used with humans suffering from Type 2 diabetes mellitus. Neither drug has been tested with cats thus far and it is currently unknown whether either of these drugs exert any effect in cats or not. The objective...

  • Dapagliflozin (BMS-512148), a Selective Inhibitor of the Sodium-Glucose Uptake Transporter 2 (SGLT2), Reduces Fasting Serum Glucose and Glucose Excursion in Type 2 Diabetes Mellitus Patients Over 14 Days. Komoroski, Bernard; Brenner, Erik; Li, Li; Vachharajani, Nimish; Kornhauser, David // Diabetes;Jun2007 Supplement 1, Vol. 56, pA49 

    The article discusses the results of a clinical study examining the ability of dapagliflozin to reduce fasting serum glucose and glucose excursion in patients with type 2 diabetes mellitus (T2DM) over 14 days. It mentions that dapagliflozin is a selective inhibitor of the sodium-glucose uptake...

  • Administrative Claims Analysis of New Exenatide Patients with Type 2 Diabetes. Wade, Ron; Quimbo, Ralph; Barron, John; Schroeder, Brock; Wintle, Matthew; Misurski, Derek; Oglesby, Alan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA561 

    Traditional antidiabetic therapies often fail to maintain glycemic control over time. In this retrospective analysis using a large, national commercial health care claims database, we describe baseline characteristics, comorbidities, and concomitant therapies in patients prescribed exenatide in...

  • Administration of Miglitol Until 30 Minutes After the Start of a Meal Is Effective in Type 2 Diabetic Patients. Terauchi, Yasuo; Aoki, Kazutaka; Nakamura, Akinobu; Nezu, Uru; Iwasaki, Tomoyuki; Takahashi, Mayumi; Kimura, Mari // Diabetes;Jun2007 Supplement 1, Vol. 56, pA562 

    Pharmacological agents are now available that primarily modify post-prandial plasma glucose levels. The alpha-glucosidase inhibitors (αGIs) represent one such class of agents whose intake is recommended just before a meal; however, adherence to these drugs has been reported to be lower than...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics